At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
CP-690,550 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Open-Label Extension Study Of CP-690,550 As Maintenance Therapy In Patients With Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating CP-690,550 for Crohn's Disease. Completed, enrolled 150 participants across 75 sites in 17 countries.
Detailed Summary
The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesAustralia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Japan, Netherlands, South Africa, South Korea, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedNov 2011
Enrollment StartApr 2012
Primary CompletionJul 2016
TodayJul 2026
First PostedNov 11, 2011
Enrollment StartApr 1, 2012
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 14.6 years ago
Interventions
CP-690,550drug
ORAL TABLET, TWICE DAILY
CP-690,550drug
ORAL TABLETS, TWICE DAILY